Product code LTP-ISO-F is supplied as an isomer-free latanoprost pharma grade active pharmaceutical ingredient with the molecular formula C₂₆H₄₀O₅, a molecular weight of 432.59 g/mol, and CAS registry number 130209-82-4. The neat substance is a clear, colorless to pale yellow viscous oil at 20–25°C. It is manufactured for development and production of low-dose tablet, capsule, granulated intermediate, oral solution, and sterile injectable formulation where residual stereoisomer content must be minimized. The API is released with a certificate of analysis that includes HPLC assay, related substances, water content, residual solvents, sulfated ash, chiral purity, and bacterial endotoxin data when the parenteral grade is ordered. The material is packaged in amber Type I borosilicate glass vials under argon headspace.

Pharmacologically, latanoprost is an isopropyl ester prodrug that undergoes esterase hydrolysis to the active free acid, a selective FP prostaglandin receptor agonist. The isomer-free grade does not alter this conversion. It reduces the level of 15(S)-epimer and 5,6-trans species that can differ in receptor interaction and can complicate low-wavelength HPLC analysis. The product is controlled under current pharmacopoeial monographs for latanoprost and under ICH Q3A(R2), ICH Q3C(R8), and ICH Q3D(R2) as applicable to the requested route of administration.

What Distinguishes the Isomer-Free Grade from Standard Latanoprost API?

Conventional latanoprost API may contain measurable amounts of the 5,6-trans isomer and other process-related stereoisomers that partially co-elute with the active peak under reversed-phase HPLC conditions. The isomer-free grade is prepared by replacing final purification steps that require prolonged heating with low-temperature chromatography and selective crystallization methods, thereby reducing the trans isomer and 15-epimer area percentages. In an HPLC-UV system using a phenyl-hexyl column and an acidified phosphate–acetonitrile mobile phase, the active peak elutes at the relative retention time of 1.00; the isomer-free grade shows no quantifiable peak at the relative retention time assigned to the 5,6-trans species. The detection wavelength is set at 205 nm. The method is validated for linearity, precision, and accuracy according to ICH Q2(R2) and is equivalent to the liquid chromatographic procedure described in USP <621> and Ph. Eur. 2.2.46.

The difference from standard latanoprost is not a different pharmacological mechanism but an impurity-profile difference. The 15(S)-epimer of latanoprost may exhibit different FP receptor binding; its reduction helps avoid pharmacological interference in receptor-binding studies and improves chromatographic specificity during low-dose assay. The isomer-free grade is controlled so that the 5,6-trans isomer does not exceed 0.15%, individual unspecified impurities do not exceed 0.10%, and total related substances do not exceed 0.5% unless otherwise required by the relevant monograph. Residual solvent and elemental impurity control for the oral grade follows ICH Q3C(R8) and ICH Q3D(R2). Class 1 solvents are not used in the final purification or packaging steps. Class 2 and Class 3 solvents, where present, are controlled below the option-2 limits or the compendial limits stated in the certificate of analysis. For the parenteral grade, elemental impurities are assessed against the parenteral permitted daily exposure values for cadmium, lead, arsenic, mercury, cobalt, vanadium, nickel, and molybdenum.

When the API is used in tablet or capsule manufacture, the neat oil cannot be directly compressed. A standard operation is to dissolve the drug substance in 96% ethanol to form a spray solution at 5–10% w/w solids, then spray the solution onto microcrystalline cellulose and colloidal silicon dioxide in a fluid-bed granulator with inlet air temperature maintained below 35°C. The resulting granules are dried to an ethanol residual not exceeding 2.0% and passed through a 500 µm screen. The dried granule D90 is controlled below 850 µm by laser diffraction according to ISO 13320. The adsorption step is monitored by loss on drying and by gas chromatography under USP <467> conditions for ethanol. Published data for the exact spray solution saturation limit in this specific configuration is limited; the range should be confirmed during formulation development.

Because the pure API is a viscous oil, the measured viscosity is determined by rotational rheometry according to ISO 3219. The value is batch-specific and should be used to set the feed-line and spray-nozzle parameters in the fluid-bed process. For low-dose solid oral development, dissolution testing is best performed in acidic media such as 0.1 N HCl or pH 4.5 acetate buffer; higher pH media accelerate ester hydrolysis and may confound the dissolution profile.

Processing-Viscosity Constraints in Low-Dose Tablet and Capsule Blending

Low-dose solid oral formulations of latanoprost typically contain 10–250 µg of active per dosage unit. This creates a content uniformity risk that is controlled by geometric dilution and by use of the isomer-free API to eliminate co-eluting impurity interference at low detection wavelengths. After fluid-bed adsorption, the granulated intermediate is blended in a bin blender with an intensifier bar and then lubricated with 0.25% magnesium stearate. Blend uniformity is tested according to USP <905>; the acceptance value for the active peak should remain ≤15 at development and scale-up.

For tablet compression, the adsorbed granules are compressed on a rotary tablet press with compression force adjusted to achieve tablet hardness of 60–100 N and friability below 1.0%, tested according to USP <1216>. The granules should be stored in low-humidity conditions before compression because adsorbed oil can soften under elevated moisture and reduce flow. If capsules are used, the granules are filled on an automatic dosator machine; fill weight is controlled to ±3% and the empty capsule shell is selected from a qualified gelatin or hypromellose type with water content below 13% to avoid moisture-induced oil desorption.

The carrier surface area is controlled because oil adsorption capacity is proportional to available surface; the value is determined by nitrogen adsorption according to USP <846>. Lot-to-lot variability in carrier surface area is a known source of blend segregation when the same process parameters are transferred across scales. During scale-up, the batch-to-batch variation of the spray-dried lactose or microcrystalline cellulose should be considered a critical material attribute because it changes the oil distribution and can produce superpotent or subpotent zones in the blend. Near-infrared spectroscopy may be used as a process analytical technology tool, but any on-line quantification model must be validated against ICH Q2(R2).

For injectable product development, the API is dissolved in a vehicle composed of ethanol, propylene glycol, and water for injection. The pH of the aqueous component is adjusted to 5.0–6.5 with dilute hydrochloric acid or sodium hydroxide to reduce ester hydrolysis. The solution is pre-filtered through a 0.45 µm PVDF membrane and sterilizing-filtered through a 0.22 µm PVDF membrane. Terminal heat sterilization is not used because latanoprost degrades through ester hydrolysis and trans-isomer formation under autoclave conditions. The isomer-free grade is preferred for injectable studies because its starting trans-isomer level is below the compendial threshold, and forced-degradation samples show a lower absolute increase in the trans isomer when compared with conventional material at the same pH and temperature.

Aqueous or partially aqueous latanoprost solutions should not be exposed to buffers above pH 7.5, strong acids, strong bases, or oxidizing agents. Under these conditions the isopropyl ester hydrolyzes to the free acid and the formation of related substances accelerates. Soft PVC and uncoated elastomer surfaces may adsorb the lipophilic oil and should be avoided in product-contact equipment unless compatibility data are available.

When Sterile Injectable Formulation Demands Endotoxin and Particulate Control

The parenteral-grade version of the API is released with a bacterial endotoxin limit of ≤0.25 EU/mg, tested according to USP <85> and Ph. Eur. 2.6.14. Bioburden is controlled before sterile filtration, and the filling operation is performed in an ISO 14644-1 Class 5 cleanroom. The final solution is filled into depyrogenated glass vials or ampoules under nitrogen overlay; subvisible particulate matter is evaluated according to USP <788>. The container closure system uses Type I borosilicate glass meeting USP <660> and elastomeric closures meeting USP <381>.

The API is not supplied as a sterile powder; therefore, aseptic filtration of the formulated solution is required for injectable products. Filtration membranes should be selected from PVDF or nylon with manufacturer validation data for the specific ethanol–propylene glycol–water mixture. The filter should be integrity-tested by bubble point or forward flow before and after filling, according to the membrane manufacturer and ISO 13408-2 guidance. If the product is intended for ophthalmic or periocular injection, the same endotoxin and particulate controls apply, but the final formulation may require isotonic adjustment with sodium chloride and pH adjustment to 5.5–6.5.

The API is supplied in 1 g, 5 g, 10 g, and 100 g quantities in amber Type I borosilicate vials sealed under argon. The recommended long-term storage temperature is −20°C; short-term storage at 2–8°C is acceptable if the material is used within the vendor-assigned retest period. The retest period is assigned from long-term and accelerated stability studies conducted according to ICH Q1A(R2). Before opening, the vial should be equilibrated in a nitrogen-purged glovebox to prevent water condensation. Repeated freeze-thaw cycles are not recommended; multiple samplings should be avoided or the API aliquoted into single-use containers under controlled atmosphere. The oil is sensitive to ultraviolet light and should be protected from direct light during all handling steps.